Zenas Biopharma’s (ZBIO) “Outperform” Rating Reiterated at Wedbush

Wedbush reaffirmed their outperform rating on shares of Zenas Biopharma (NASDAQ:ZBIO) in a report published on Thursday morning,RTT News reports. They currently have a $35.00 price objective on the stock.

Separately, Guggenheim reaffirmed a “buy” rating and issued a $45.00 price target on shares of Zenas Biopharma in a research note on Wednesday, March 12th.

Zenas Biopharma Stock Up 12.2%

Shares of Zenas Biopharma stock opened at $9.74 on Thursday. The stock has a 50 day moving average of $8.88. The stock has a market cap of $407.46 million and a PE ratio of -2.74. Zenas Biopharma has a one year low of $5.83 and a one year high of $26.25.

Zenas Biopharma (NASDAQ:ZBIO) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.80) EPS for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.35.

Hedge Funds Weigh In On Zenas Biopharma

Several hedge funds have recently made changes to their positions in ZBIO. New York State Common Retirement Fund purchased a new position in shares of Zenas Biopharma during the first quarter valued at approximately $49,000. Jefferies Financial Group Inc. purchased a new position in shares of Zenas Biopharma during the first quarter valued at approximately $348,000. Finally, Nuveen LLC purchased a new position in shares of Zenas Biopharma during the first quarter valued at approximately $250,000.

About Zenas Biopharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.